Meet Gert Ossenkoppele, our Volunteer of the Month

Voulenteer of the month Gert Ossenkoppele

I am lucky to be one of the first members of the EHA (member number 34). I am involved as volunteer since 2009...

Read more

Call for urgent action on medicine shortages in Europe

michal parzuchowski 7TWRwDjfGew unsplash

EPHA published a position paper on medicine shortages in Europe. EHA welcomes its  recommendations to address the increasing shortages crisis, which threatens patient outcomes and patient safety.

Read more

EHA-ISHBT Hematology Tutorial 2020

WhatsApp Image 2020 04 07 at 14.09.46

The 4th EHA-ISHBT Hematology Tutorial on Hematological Disorders was held on February 28 and 29 in Chandigarh, India, and chaired by Prof John Gribben, Prof Neelam Varma and Prof Pankaj Malhotra.

Read more

Guidelines for hematologists

AdobeStock 293330068

EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases. View the EHA methodology for guidelines, EHA Guidelines by topic and Guidelines produced by other societies and endorsed by EHA

Read more

Recommendation for hematologists in COVID-19 crisis

Recommendations FAQ

As COVID19 progresses limited information is available in hematology to manage patient care during the pandemic. The EHA Scientific Working Group Infections in Hematology has developed key questions and answers to stand by hematology professionals in the COVID19 crisis.

Read more

EHA statement on coronavirus (COVID-19)

AdobeStock 320164385 homepage

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Voulenteer of the month template website Eva Hellstroem Lindberg

I was nominated to be on the EHA Ballot in 2000 and to my surprise and happiness, I was elected as Councilor. I became President-elect in 2003 and was the EHA President 2005-2007.

Read more

ATMPs and CAR-T: the uptake challenge

HemAffairs ATMPs and CAR T

Advanced therapy medicinal products (ATMPs) are a game changer for improving the lives of patients with severe to life-threatening diseases. Yet, despite fast-paced innovation in the field, few ATMPs have reached the EU market and benefited patients. The challenges facing their adoption by health systems are complex. A test case is the uptake of CAR T-cell therapy; what are the hurdles and what action is needed from stakeholders?

Read more

EU health policy: limited scope, high ambition

HemAffairs EU health policy

While health policy remains the primary responsibility of Member States, in many areas the added value of EU-level collaboration and harmonization has increased. EU initiatives in health have shown a mixed record in terms of impact, but hopes are high for the latest one, the ambitious Europe’s Beating Cancer Plan.

Read more

Meet Helen Papadaki, our January volunteer of the month

Helen Papadaki website

I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on Granulocytes &...

Read more

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

IMG 2537

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

November 22-24, 2019 |Madrid, Spain

Read more

A well-attended second meeting from the European Hematology Association (EHA) an...

WhatsApp Image 2019 12 18 at 16.38.59 7

For the second time the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron joined in the organization of the meeting focused on Red...

Read more

Meet Michaela Gruber, our December volunteer of the month

Michaela Gruber website
Dr Michaela Gruber was one of the initiators of YoungEHA as well as a founding member of the YoungEHA Committee. Meet Michaela Gruber and learn about what she does and why she has been volunteering for EHA for all these years.
Read more

Revising the ICH Guidelines on Clinical Trials

Delegation HemAffairs

Clinical trials and drug development have become more complex over the years. One complicating factor is the increased administrative burden, as was pointed out in the previous edition of HemAffairs. Doctors and clinical researchers are more and more bound to rules they deem neither necessary nor effective. At first sight, the requirements for clinical trials seem clear and thorough. Nonetheless, the interpretation and implementation of these rules leave room for improvement.

Read more

The past and future of the EU Blood, Tissues and Cells legislation

Annake HemAffairs HR

Blood, tissues and cells (BTC) are used in medicine and in hematology on a daily basis. EU legislation has been in place for over 15 years to regulate those practices, and to ensure safety and quality standards for substances of human origin (SoHO). For instance, through technical and traceability requirements for BTC, the reporting of serious adverse reactions (SARs), and verification procedures for imported BTC.

Read more